AI is about to change healthcare. These 6 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
For someone looking at Kajima today, the core belief is that a mature, large-scale contractor can still create value through disciplined profitability and measured capital returns, even if headline growth is modest and the share price has lagged the broader market recently. The latest quarter fits that story: sales and revenue softened, but net income and EPS improved, suggesting project mix and execution mattered more than top line. At the same time, guidance for fiscal 2027 points to steady earnings while the dividend reset, with a higher interim payout but lower full-year level versus last year, hints at tighter cash flow management and possibly lumpier project timing. Combined with ongoing buybacks and governance changes after the CEO transition, these moves subtly shift short term catalysts toward margins, order quality, and capital allocation, while keeping risks around slower growth and execution firmly in focus.
However, the recalibrated dividend policy is a new signal investors should understand closely. Despite retreating, Kajima's shares might still be trading above their fair value and there could be some more downside. Discover how much.Explore 2 other fair value estimates on Kajima - why the stock might be worth just ¥7321!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com